References
- Lawn J. C. Federal Register 1985; 50: 23118–23120
- Buchanan J. Ecstasy in the emergency department. Clinical Toxicology Update 1985; 7, San Francisco Bay Area Regional Poison Center
- Ricaurte G., Bryan G., Strauss L. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985; 229: 986–988
- Linden C. H., Kulig K. W., Rumack B. H. Amphetamines. Topics Emerg Med 1985; 7: 1–8
- Linden C. H., Rumack B. H., Strehlke C. Monoamine oxidase inhibitor overdose. Ann Emerg Med 1984; 13: 1137–1144
- Baldessarini R. J. Drugs and the treatment of psychiatric disorders. Goodman and Gilman's The Pharmacological Bases of Therapeuticsed 7, A. G. Gilman, L. S. Goodman, T. W. Rall, M. Murad. MacMillan, New York 1985; 423–426
- Goldberg L. I. Monoamine oxidase inhibitors: Adverse reactions and possible mechanisms. JAMA 1964; 190: 132–138
- Sjoquist F. Psychotropic drugs (2): Interaction between monoamine oxidase inhibitors (MAOI) and other substances. Proc Roy Soc Med 1965; 58: 967–975
- Krisko I., Lewis E., Johnson J. E. Severe hyperpyrexia due to tranylcypromine‐amphetamine toxicity. Ann Intern Med 1969; 70: 559–564
- Lloyd J. T. A., Walker D. R. H. Death after combined dexamphetamine and phenelzine (Letter). Br Med J 1965; 2: 168–169
- Dally P. J. Fatal reaction associated with tranylcypromine and methylamphetamine (Letter). Lancet 1982; 1: 1235–1236
- Smookler S., Bermudez A. J. Hypertensive crisis resulting from an MAO inhibitor and an over‐the‐counter appetite suppressant. Ann Emerg Med 1982; 11: 482–484
- Horler A. R., Wynne N. A. Hypertensive crisis due to pargyline and metaraminol. Br Med J 1965; 2: 460–461
- Stark D. C.C. Effects of giving vasopressors to patients on monamine‐oxidase inhibitors (Letter). Lancet 1962; 1: 1405–1406
- Elis J., Lawrence D. R., Mattie H. Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. Br Med J 1967; 2: 75–78
- Boakes A. J., Laurence D. R., Teoh P. C. Interactions between sympathomimetic amines and antidepressants in man. Br Med J 1973; 1: 311–315
- Zeck P. The dangers of some antidepressant drugs (Letter). Med J Aust 1961; 2: 607–608
- Sherman M., Hanser G. C., Glover B. H. Toxic reactions to tranylcypromine. Am J Psychiatry 1964; 120: 1019–1021
- Horwitz D., Goldberg L. I., Sjoerdsma A. Increased blood pressure responses to dopamine and norepinephrine produced by monoamine oxidase inhibitors in man. J Lab Clin Med 1960; 56: 747–753
- Weiner N. Norepinephrine, epinephrine, and the sympathomimetic amines. Goodman and Gilman's the Pharmacological Basis of Therapeuticsed. 7, A. G. Gilman, L. S. Goodman, T. W. Rall, M. Murad. MacMillan, New York 1985; 145–180
- Nichols D. E., Lloyd D. H., Hoffman A. J. Effects of certain hallucinogenic amphetamine analogues on the release of [3H] serotonin from rat brain synaptosomes. J Med Chem 1982; 25: 530–535
- Grinspoon L., Hedblom P. The speed culture: Amphetamine use and abuse in America. Harvard University Press, Cambridge, Mass 1975; 40–61
- Cuthbert M. F., Greenberg M. P., Morley S. W. Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors. Br Med J. 1969; 1: 404–406
- Seller R. H. Idiopathic orthostatic hypotension: Report of a successful treatment with a new form of therapy. Am J Cardiol 1969; 23: 838–844
- Robinson D. S., Cooper T. B., Jindal S. P. Metabolism and pharmacokinetics of phenelzine: Lack of evidence for acetylation pathway in humans. J Clin Psychopharmacol 1985; 5: 333–337